Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Index Generated for Diagnosing Non-Alcoholic Fatty Liver Disease

By LabMedica International staff writers
Posted on 31 Jan 2017
Based on clinical data, researchers have generated a new fatty liver index (FLI) that can predict the presence of fatty liver disease (FLD) with high accuracy, enabling development of an extended, more effective diagnostic index for nonalcoholic fatty liver disease (NA-FLD), which has become an epidemic in industrialized countries.

There is not only a great interest worldwide to understand the causes and consequences of FLD, but also to diagnose it at an early stage. More...
Under the direction of Professor Norbert Stefan, researchers of the Department of Internal Medicine IV of Tübingen University Hospital and the Institute for Diabetes Research and Metabolic Diseases (IDM) of Helmholtz Zentrum München as well as of the German Institute for Nutrition and Health (DIfE), both partners of the German Center for Diabetes Research, succeeded in improving on the current diagnostic index.

Approximately every third adult in the industrialized countries has a morbidly fatty liver. For these people, this not only increases the risk of advanced liver diseases such as liver cirrhosis and liver cancer, but also in particular type 2 diabetes and cardiovascular diseases. To be able to intervene early with preventive and therapeutic measures, the fatty liver must be detected in time. The ultrasound liver examination and the determination of the liver values are suitable, but in most cases they can only diagnose the fatty liver in an advanced stage. More sophisticated tests such as magnetic resonance spectroscopy are more meaningful, but they are not widely applicable because of the relatively high costs in clinical practice.

Therefore, scientists are working on simple accurate diagnostic methods that would be more suitable. Among various indices that have been developed, the Fatty Liver Index (FLI) consisting of the parameters age, waist circumference, and triglyceride levels (TG) measured in the blood in a fasting state, and gamma-glutamyl transpeptidase (GGT), has been shown to be quite effective.

The researchers from Tübingen led by Prof. Stefan, in collaboration with Prof. Schulze of DIfE, and their colleagues from Hamburg and Italy, have developed an improved FLI. For this purpose, in addition to the parameters of the FLI, they used the TG and glucose levels from an oral glucose tolerance test measured at the time point of 2 hours, as well as the most important gene variant for fatty liver (rs738409 C>G in PNPLA3). On the basis of data from the TULIP (Tübingen Lifestyle Intervention Program) study, they were able to show that with this new, extended FLI, not only can the fatty liver be diagnosed better than with the known FLI, but also the probability of reducing liver fat content during a lifestyle intervention can be more precisely determine.

We hope that “this index will be increasingly used in clinical practice to diagnose fatty liver disease at an early stage in order to prevent the consequences of fatty liver disease,” said Prof. Stefan.

The study, by Kantartzis K et al, was published online January 14, 2017, in the journal Diabetes & Metabolism.


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Hemodynamic System Monitor
OptoMonitor
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: PD-1 protein blockade is the standard treatment for advanced melanoma among the different types of immunotherapy (Photo courtesy of 123RF)

Precision Tool Predicts Immunotherapy Treatment Failure in Melanoma Patients

Melanoma, though accounting for only about 4% of skin tumors, is the deadliest form of skin cancer due to its high potential to metastasize. While immunotherapy, especially PD-1 protein blockade, has revolutionized... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.